Compare Koninklijke Philips NV (PHG) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Xpeng Inc - ADR — how do they compare? Koninklijke Philips NV trades at $24.17 (market cap $23.52B), while Xpeng Inc - ADR trades at $9.92 (market cap $9.16B). The key difference: Koninklijke Philips NV is far larger — about 2.6× Xpeng Inc - ADR's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Xpeng Inc - ADR for 80 Days on average.
| PHG | XPEV | |
|---|---|---|
Market Cap | $23.52B | $9.16B |
Volume | 1,635,069 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.91 | $28.07 |
52-Week Low | $23.81 | $9.25 |
Typical Hold Time | 84 Days | 80 Days |
Enterprise Value | $29.87B | $11.09B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.
XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
